Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

155.16 +2.04 (+1.33%)
Streaming Delayed Price Updated: 12:43 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
57 58 Next >
News headline image
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth. 
Via MarketBeat
Topics Economy
News headline image
Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis
Get Oral Cancer Treatment Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
News headline image
AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise
Stay up-to-date with AI for Pharma and Biotech Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Topics Artificial Intelligence
News headline image
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker ↗
Eylea sales fell and missed expectations in the U.S. 
Via Investor's Business Daily
News headline image
Is This Big Pharma Stock a Buy for Dividend Investors? ↗
The Swiss pharmaceutical giant possesses a tremendous product pipeline. 
Via The Motley Fool
News headline image
Why Novartis Stock Is Trading Higher Today ↗
 
Via Benzinga
News headline image
Earnings Preview: Novartis ↗
 
Via Benzinga
News headline image
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗
 
Via Benzinga
News headline image
What's Going On With Immix Biopharma Stock Today ↗
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG' 
Via Benzinga
News headline image
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents ↗
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several... 
Via Benzinga
News headline image
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know ↗
 
Via Benzinga
News headline image
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
News headline image
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels ↗
Novartis AG (NYSE: NVS) released detailed  
Via Benzinga
News headline image
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines ↗
In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam. 
Via Benzinga
News headline image
Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise ↗
Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations. 
Via Investor's Business Daily
News headline image
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
 
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
All three companies have therapies with strong sales potential. 
Via The Motley Fool
News headline image
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
News headline image
Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment ↗
 
Via Benzinga
News headline image
Why Shares of Legend Biotech Jumped Wednesday ↗
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt. 
Via The Motley Fool
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
Via Investor Brand Network
News headline image
2 Best Biotech Stocks to Buy for the Long Haul ↗
These two are among the largest pharma companies in the world. 
Via The Motley Fool
News headline image
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late ↗
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
News headline image
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says ↗
 
Via Benzinga
News headline image
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer? ↗
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or... 
Via Benzinga
News headline image
Trillions In Biotech Stock Gains Trace Back To This Financier ↗
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
News headline image
Epic Growth Story Predicted for Pharmaceutical Drug Delivery Market's Future: Johnson & Johnson, Novartis International, Merck
Stay up-to-date with Pharmaceutical Drug Delivery Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher
Tilray Brands moves lower on mixed results, but the bottom may be in, with positive FCF expected this quarter. The long-term catalyst is US legalization. 
Via MarketBeat
Topics Cannabis
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.